The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial of neoadjuvant pegylated arginine deiminase (ADI-PEG 20) with ifosfamide and radiotherapy in soft tissue sarcomas (STS) of the trunk or extremity.
 
Mia C. Weiss
No Relationships to Disclose
 
Sasha Haarberg
Honoraria - Wolters Kluwer
 
Chongliang Luo
No Relationships to Disclose
 
Angela C. Hirbe
Honoraria - Empartners
Consulting or Advisory Role - Alexion Pharmaceuticals; AstraZeneca; Intellisphere, LLC; SpringWorks Therapeutics
Research Funding - Tango Therapeutics
Patents, Royalties, Other Intellectual Property - Boehringer Ingelheim RCV GmBH & Co KG- Licensing- T-019044 Development of a Preclinical NF1-MPNST Platform Suitable for Precision Oncology Drug Discovery and Evaluation. Royalities paid through the University; Deutsches Krebsforschungszentrum-licensing agreement for PDX cell lines. Paid through the University. (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; SpringWorks Therapeutics
 
Anthony J. Apicelli
No Relationships to Disclose
 
D. Ian English
No Relationships to Disclose
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Iterion Therapeutics, Inc; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; ADRx; Advenchen Laboratories; Agenus; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Boxer Capital LLC; Curis; Daiihi Sankyo; Deciphera; Deciphera Pharmaceuticals,; EcoR1 Capital; Epizyme; Hinge Bio, Inc.; Intellisphere; Kronos Bio, Inc.; PTC Therapeutics; PTC Therapeutics; Putnam Associates; Race Oncology; Regeneron; Salarius Pharmaceuticals, Inc.,
Research Funding - GlaxoSmithKline; Merck; Pfizer; Polaris; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc